Literature DB >> 18356307

Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.

V A Harpin1.   

Abstract

In recent years the medication options for the treatment of ADHD in children and young people have increased. The National Institute for Health and Clinical Excellence (NICE) produced updated guidelines in 2006. This paper aims to interpret these guidelines by reviewing the medication options in light of relevant research and clinical practice. The properties of methylphenidate, dexamfetamine and atomoxetine are discussed.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18356307     DOI： 10.1136/adc.2006.106864

Source DB:  PubMed          Journal:  Arch Dis Child Educ Pract Ed        ISSN： 1743-0585            Impact factor:   1.309


  7 in total

1.  Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.

Authors:  Christopher L Robinson; Katelyn Parker; Saurabh Kataria; Evan Downs; Rajesh Supra; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Health Psychol Res       Date:  2022-09-23

Review 2.  Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Karly P Garnock-Jones; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  Attention-deficit hyperactive disorder presenting with school truancy in an adolescent: a case report.

Authors:  Noor Azimah Muhammad; Wan Salwina Wan Ismail; Chai Eng Tan; Aida Jaffar; Shalisah Sharip; Khairani Omar
Journal:  Ment Health Fam Med       Date:  2011-12

4.  Epilepsy, Attention-Deficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence.

Authors:  Monidipa Ravi; Abel Ickowicz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2016-02-01

5.  In transition with ADHD: the role of information, in facilitating or impeding young people's transition into adult services.

Authors:  Anna Price; Tamsin Newlove-Delgado; Helen Eke; Moli Paul; Susan Young; Tamsin Ford; Astrid Janssens
Journal:  BMC Psychiatry       Date:  2019-12-17       Impact factor: 3.630

6.  High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report.

Authors:  Michael Liebrenz; Danielle Hof; Anna Buadze; Rudolf Stohler; Dominique Eich
Journal:  J Med Case Rep       Date:  2012-05-14

7.  A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.

Authors:  Jihyung Hong; Tatiana Dilla; Jorge Arellano
Journal:  BMC Psychiatry       Date:  2009-04-14       Impact factor: 3.630
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.